Mettler-Toledo International Inc. (0K10.L)
USD 1248.03
(-0.62%)
USD 1248.03
(-0.62%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.16 Billion USD | -6.07% |
| 2022 | 1.24 Billion USD | 12.37% |
| 2021 | 1.09 Billion USD | 24.93% |
| 2020 | 885.95 Million USD | 8.04% |
| 2019 | 811.97 Million USD | 6.43% |
| 2018 | 770.52 Million USD | 11.9% |
| 2017 | 684.81 Million USD | 12.65% |
| 2016 | 599.98 Million USD | 5.41% |
| 2015 | 557.67 Million USD | 11.51% |
| 2014 | 518.08 Million USD | 5.94% |
| 2013 | 489.05 Million USD | 5.4% |
| 2012 | 464.02 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 286.87 Million USD | 4.88% |
| 2024 Q1 | 279.85 Million USD | -4.2% |
| 2023 Q3 | 308.15 Million USD | -3.67% |
| 2023 Q1 | 278.47 Million USD | -24.82% |
| 2023 Q4 | 294.32 Million USD | -4.49% |
| 2023 Q2 | 319.89 Million USD | 14.88% |
| 2023 FY | - USD | -3.1% |
| 2022 FY | - USD | 12.37% |
| 2022 Q3 | 318.84 Million USD | 7.4% |
| 2022 Q2 | 296.87 Million USD | 17.29% |
| 2022 Q1 | 253.12 Million USD | -23.44% |
| 2022 Q4 | 370.39 Million USD | 16.17% |
| 2021 Q3 | 283.98 Million USD | 6.53% |
| 2021 Q4 | 330.61 Million USD | 16.42% |
| 2021 Q1 | 221.61 Million USD | -25.22% |
| 2021 Q2 | 266.57 Million USD | 20.29% |
| 2021 FY | - USD | 24.93% |
| 2020 Q2 | 179.88 Million USD | 24.58% |
| 2020 Q4 | 296.36 Million USD | 26.87% |
| 2020 FY | - USD | 8.04% |
| 2020 Q1 | 144.39 Million USD | -44.07% |
| 2020 Q3 | 233.6 Million USD | 29.86% |
| 2019 FY | - USD | 6.43% |
| 2019 Q4 | 258.18 Million USD | 29.75% |
| 2019 Q3 | 198.98 Million USD | 10.53% |
| 2019 Q2 | 180.02 Million USD | 19.8% |
| 2019 Q1 | 150.27 Million USD | -37.95% |
| 2018 Q1 | 142.21 Million USD | -34.99% |
| 2018 Q3 | 184.6 Million USD | 7.42% |
| 2018 FY | - USD | 11.9% |
| 2018 Q2 | 171.86 Million USD | 20.85% |
| 2018 Q4 | 242.19 Million USD | 31.19% |
| 2017 FY | - USD | 12.65% |
| 2017 Q2 | 147.65 Million USD | 16.27% |
| 2017 Q4 | 218.75 Million USD | 33.61% |
| 2017 Q3 | 163.71 Million USD | 10.88% |
| 2017 Q1 | 126.99 Million USD | -36.86% |
| 2016 Q4 | 201.14 Million USD | 31.22% |
| 2016 FY | - USD | 5.41% |
| 2016 Q3 | 153.28 Million USD | 17.67% |
| 2016 Q2 | 130.27 Million USD | 25.82% |
| 2016 Q1 | 103.53 Million USD | -43.74% |
| 2015 Q2 | 120.66 Million USD | 21.02% |
| 2015 Q3 | 136.39 Million USD | 13.03% |
| 2015 FY | - USD | 11.51% |
| 2015 Q1 | 99.7 Million USD | -44.21% |
| 2015 Q4 | 184.02 Million USD | 34.93% |
| 2014 Q4 | 178.71 Million USD | 37.69% |
| 2014 FY | - USD | 5.94% |
| 2014 Q1 | 93.87 Million USD | -44.19% |
| 2014 Q2 | 115.7 Million USD | 23.25% |
| 2014 Q3 | 129.79 Million USD | 12.18% |
| 2013 Q2 | 110.67 Million USD | 22.14% |
| 2013 Q3 | 119.55 Million USD | 8.03% |
| 2013 Q4 | 168.21 Million USD | 40.7% |
| 2013 FY | - USD | 5.4% |
| 2013 Q1 | 90.61 Million USD | -42.88% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | 158.65 Million USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Editas Medicine, Inc. | -163.11 Million USD | 813.627% |
| Dynavax Technologies Corporation | 9.66 Million USD | -11942.696% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | -1084.636% |
| Perrigo Company plc | 646.2 Million USD | -80.137% |
| Illumina, Inc. | -608 Million USD | 291.455% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 89.222% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 359.246% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 110.321% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 64.249% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 1221.519% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 74.989% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 3222.192% |
| Waters Corporation | 1.02 Billion USD | -13.871% |
| Biogen Inc. | 2.37 Billion USD | 51.029% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 1431.45% |
| Evolus, Inc. | -41.81 Million USD | 2884.135% |
| Adicet Bio, Inc. | -136.53 Million USD | 952.563% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 1089.415% |
| bluebird bio, Inc. | -167.16 Million USD | 796.363% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 875.473% |
| FibroGen, Inc. | -261.4 Million USD | 545.304% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 30.588% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 2719.562% |
| Homology Medicines, Inc. | -47.75 Million USD | 2537.488% |
| Geron Corporation | -174.78 Million USD | 765.999% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 610.276% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 1364.183% |
| Myriad Genetics, Inc. | -67.8 Million USD | 1816.883% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 1254.499% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 329.906% |
| Zoetis Inc. | 3.68 Billion USD | 68.411% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 2401.762% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | -275.155% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 74.723% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 3326.116% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 606.085% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 537.617% |
| Verastem, Inc. | -83.16 Million USD | 1499.667% |
| Nektar Therapeutics | -243.1 Million USD | 578.821% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 617.375% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | 1423.006% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 365.04% |
| OPKO Health, Inc. | -65.51 Million USD | 1876.737% |
| Exelixis, Inc. | 196.6 Million USD | -492.083% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | -179.752% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | -974.598% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 2187.752% |
| uniQure N.V. | -253.1 Million USD | 559.916% |
| Imunon, Inc. | -20.78 Million USD | 5701.153% |
| Blueprint Medicines Corporation | -474.61 Million USD | 345.263% |
| Insmed Incorporated | -654.73 Million USD | 277.788% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | -157.563% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 436.951% |
| TG Therapeutics, Inc. | 26.1 Million USD | -4359.95% |
| Incyte Corporation | 919.42 Million USD | -26.606% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 330.368% |